What did the phase 2 obesity trial measure?
The 2023 randomised trial enrolled 338 adults and assessed changes in body weight over 48 weeks. It reported greater mean weight reduction in Retatrutide groups than with placebo. Gastrointestinal adverse events were common and dose-related; dose-dependent heart-rate increases were also reported.
An obesity-treatment trial must be read alongside its participant criteria, adverse events and follow-up duration. Weight loss measured in that setting is not a promised result for another material, and body weight is not the same as directly measured fat mass.
Sources: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
How is liver-fat research different?
A 2024 phase 2a report examined liver fat using MRI in participants with metabolic dysfunction-associated steatotic liver disease. An imaging change is a specific endpoint. It does not, on its own, demonstrate fewer long-term liver complications.
What does the phase 3 diabetes publication add?
The 2026 TRANSCEND-T2D-1 publication reports a randomised phase 3 study in people with type 2 diabetes. Its principal question concerns glycaemic control, including HbA1c, rather than the same population and endpoint as the earlier obesity trial. Comparisons between separate trials require attention to those differences.
Sources: TRANSCEND-T2D-1: efficacy and safety of Retatrutide in type 2 diabetes
Do these papers validate a Zynx product?
No. The papers describe the investigators' study materials and methods. They do not test, certify or endorse a Zynx product. A research citation is not a batch certificate, purchasing recommendation or instruction for human use.
Use the linked publications to inspect methods, results, adverse events and disclosures. Our research library also presents structured records for these studies and a body-composition substudy. Zynx does not offer Retatrutide for purchase on this site.
Sources and further reading
This guide summarises selected sources. Original publications contain the full methods, results and disclosures; the selection is not a systematic review.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (external)
Jastreboff et al. New England Journal of Medicine (2023). Randomised human trial.
- Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (external)
Sanyal et al. Nature Medicine (2024). Liver-imaging study.
- TRANSCEND-T2D-1: efficacy and safety of Retatrutide in type 2 diabetes (external)
Bajaj et al. The Lancet (2026). Randomised phase 3 human trial.
Continue exploring
Published study records · Quality documentation · Research peptide catalogue